OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Reports

Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), emphasizing significant regulatory progress for the company’s lead candidate, OST-HER2, in treating recurrent, fully resected, pulmonary metastatic osteosarcoma. According to the report, OS Therapies has moved from Phase 2b-supported planning toward a defined global approval pathway, driven by increased regulatory clarity from both the European Medicines Agency (EMA) and Australia’s Therapeutic Goods Administration (TGA).

The key development is the EMA’s initiation of a rolling review of the OST-HER2 Conditional Marketing Authorization (CMA) dossier. Additionally, the EMA and TGA have aligned on 3-year overall survival as the approvable efficacy endpoint. This alignment provides a clear regulatory target for the company, reducing uncertainty for investors. Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, shifting the investment debate from early proof-of-concept toward execution across a dense 2026 catalyst calendar.

Stonegate outlines several upcoming milestones that will shape OST-HER2’s path to market. These include 2.5-year overall survival (OS) data in mid-second quarter 2026, meetings with the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in the second quarter, Phase 3 trial initiation in Australia in the third quarter, 3-year OS data in early fourth quarter, and a potential EMA CMA decision in the fourth quarter of 2026.

The report notes that survival data remain the key catalyst stack. The mid-2Q26 2.5-year OS data and early-4Q26 3-year OS data should determine whether OS Therapies can complete the EMA CMA submission and sustain accelerated-access momentum. Regulatory clarity is seen as the core value inflection, with the EMA rolling review, TGA endpoint alignment, MHRA ATMP designation, and upcoming FDA/MHRA meetings shifting OST-HER2 from Phase 2b validation toward an executable global approval pathway.

Financing and potential priority review voucher (PRV) optionality bridge the regulatory window. The company’s $5.25 million raise, plus expected $4.0 million in non-dilutive funding, supports 2026 catalysts. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million.

For more details, Stonegate Capital Partners encourages viewing the full announcement, including downloadable images and bios, here. The report underscores that OS Therapies is advancing toward a potential approval that could address an unmet need in osteosarcoma, a rare bone cancer with limited treatment options.

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Reports.

The post OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Reports appeared first on citybuzz.